We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+54.95%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$322M
Cap. Flow
+$104M
Cap. Flow %
9.75%
Top 10 Hldgs %
58.42%
Holding
77
New
21
Increased
11
Reduced
14
Closed
24

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$67.6M
2
GPCR icon
Structure Therapeutics
GPCR
+$32.7M
3
AMAM
Ambrx Biopharma Inc
AMAM
+$22.6M
4
VTYX
Ventyx Biosciences
VTYX
+$16.9M
5
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$14.1M

Top Sells

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$23.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$19.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$16.9M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$15.4M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 83.95%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLRN
26
DELISTED
ACELYRIN
SLRN
$9.32M 0.87%
+1,250,000
New +$10.7M
MLTX icon
27
MoonLake Immunotherapeutics
MLTX
$1.65B
$9.06M 0.85%
+150,000
New +$7.73M
ATYR
28
aTyr Pharma
ATYR
$47.4M
$8.25M 0.77%
+5,850,000
New +$7.5M
IOVA icon
29
CALL
Iovance Biotherapeutics
IOVA
$2.2B
$8.13M 0.76%
1,000,000
– –
FULC icon
30
Fulcrum Therapeutics
FULC
$247M
$8.1M 0.76%
+1,200,000
New +$5.32M
ALLK
31
DELISTED
Allakos
ALLK
$7.92M 0.74%
2,900,000
-1,750,000
-38% -$3.94M
ZNTL icon
32
CALL
Zentalis Pharmaceuticals
ZNTL
$320M
$7.58M 0.71%
+500,000
New +$7.29M
TRML
33
DELISTED
Tourmaline Bio
TRML
$7.44M 0.69%
+284,372
New +$5.69M
RNAM
34
DELISTED
Avidity Biosciences
RNAM
$7.01M 0.65%
+775,000
New +$5.18M
SLN
35
Silence Therapeutics
SLN
$553M
$6.95M 0.65%
+400,000
New +$4.49M
XENE icon
36
Xenon Pharmaceuticals
XENE
$6.32B
$6.91M 0.64%
150,000
-300,000
-67% -$10.6M
NMRA icon
37
Neumora Therapeutics
NMRA
$291M
$6.52M 0.61%
+382,345
New +$4.69M
RCUS icon
38
Arcus Biosciences
RCUS
$3.58B
$6.21M 0.58%
+325,000
New +$5.19M
MORF
39
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$5.78M 0.54%
+200,000
New +$4.76M
APLT
40
DELISTED
Applied Therapeutics
APLT
$5.56M 0.52%
+1,660,000
New +$4.13M
VTYX
41
DELISTED
Ventyx Biosciences
VTYX
$4.94M 0.46%
2,000,000
+1,775,000
+789% +$16.9M
ICVX
42
DELISTED
Icosavax, Inc. Common Stock
ICVX
$4.73M 0.44%
300,000
-2,465,741
-89% -$23.7M
RPTX
43
DELISTED
Repare Therapeutics
RPTX
$4.38M 0.41%
600,000
+300,000
+100% +$1.68M
CMPS
44
Compass Pathways
CMPS
$1.52B
$4.38M 0.41%
500,000
-450,000
-47% -$2.91M
ELVN icon
45
Enliven Therapeutics
ELVN
$3.86B
$4.25M 0.4%
307,076
– –
ATXS
46
DELISTED
Astria Therapeutics
ATXS
$4.19M 0.39%
544,960
– –
INBX
47
DELISTED
Inhibrx, Inc. Common Stock
INBX
$3.8M 0.35%
+100,000
New +$2.14M
SYRE icon
48
Spyre Therapeutics
SYRE
$8.63B
$3.23M 0.3%
150,000
-60,000
-29% -$827K
KNSA icon
49
Kiniksa Pharmaceuticals
KNSA
$4.88B
$2.63M 0.25%
+150,000
New +$2.47M
DCTH icon
50
Delcath Systems
DCTH
$415M
$1.25M 0.12%
300,000
-744,444
-71% -$2.44M
1
2
3 4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2023 Portfolio in Review

As of Q4 2023, Logos Global Management held 77 positions worth $1.07B, up 43% from $750M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Logos Global Management deployed $104M of net new capital in Q4 2023, opening 21 new positions and adding to 11 existing holdings. Its largest new stake was argenx: 145,000 shares worth $55.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Icosavax, Inc. Common Stock, an estimated $23.7M trimmed.

  • Logos Global Management's largest Q4 2023 buy was argenx: 145,000 shares worth $55.2M.
  • Logos Global Management added most to Structure Therapeutics in Q4 2023, an estimated $32.7M increase.
  • Logos Global Management's biggest Q4 2023 reduction was Icosavax, Inc. Common Stock, cutting an estimated $23.7M.
  • Logos Global Management fully exited Sarepta Therapeutics in Q4 2023, selling an estimated $19.2M.
  • Logos Global Management's ten largest holdings make up 58% of its $1.07B portfolio in Q4 2023.
  • Logos Global Management opened 21 new positions and closed 24 in Q4 2023.
  • Logos Global Management's portfolio value rose 43% quarter-over-quarter to $1.07B.

Based on Logos Global Management's 13F filing for Q4 2023, filed 14 Feb 2024.